In vitro studies, such as treating cancer cell lines with small-molecule inhibitors (e.g., SRC inhibitors like dasatinib or trametinib) or inducing mitophagy via PINK1 activators, could further elucidate the therapeutic relevance of these genes in overcoming drug resistance. This evidence concerns the gene PINK1 and cancer.